Actelion sees Corporate Governance as the underpinning foundation for maximising value creation for its shareholders through adoption of and compliance with applicable laws and best practices as a public company.
Actelion's Board is independent, diverse and experienced. It is composed of ten directors from six different nationalities, nine of whom are independent The directors bring expertise and experience from years of service as CEOs, CFOs, and COOs of some of the world’s most important biotech and pharmaceutical companies as well as other global corporations and professional bodies.
The board adheres to the highest standards of corporate governance, and provides rigorous oversight of the company and its management team, via regular meetings, both as a full board and in various sub-committees. The Board regularly reviews and benchmarks business, operational, and financial performance and assesses the M&A environment and evaluates the financial plan and related valuation analyses.
The Board continuously reviews Actelion's strategic positioning.